Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
Curr Pharm Des. 2024;30(27):2129-2141. doi: 10.2174/0113816128313713240628063301.
INTRODUCTION: Luteolin (LUT), a naturally occurring flavonoid found in vegetables, fruits, and herbal medicines, has been extensively studied for its pharmacological activities, including anti-proliferative and anticancer effects on various cancer lines. It also exhibits potent antioxidant properties and pro-apoptotic activities against human cancers. However, its therapeutic potential is hindered by its poor solubility in water (5 μg/ml at 45°C) and low bioavailability. This research on the development of luteolin-loaded nanocarrier aims to overcome these limitations, thereby opening up new possibilities in cancer treatment. METHODS: This paper covers several nanoformulations studied to increase the solubility and bioavailability of LUT. The physicochemical characteristics of the nanoformulation that influence luteolin's solubility and bioavailability have been the subject of more in-depth investigation. Furthermore, it examines how LUT's anti-inflammatory and antioxidant properties aid in lessening the side effects of chemotherapy. RESULTS: Most nanoformulations, including phytosomes, lipid nanoparticles, liposomes, protein nanoparticles, polymer micelles, nanoemulsions, and metal nanoparticles, have shown promising results in improving the solubility and bioavailability of LUT. This is a significant step forward in enhancing the therapeutic potential of LUT in cancer treatment. Furthermore, the study found that LUT's ability to scavenge free radicals can significantly reduce the side effects of cancer treatment, further highlighting its potential to improve patient outcomes. CONCLUSION: Nanoformulations, because of their unique surface and physiochemical properties, improve the solubility and bioavailability of LUT. However, poor in-vitro and in-vivo correlation and scalability of nanoformulations need to be addressed to achieve good clinical performance of LUT in oncology.
简介:木犀草素(LUT)是一种天然存在的类黄酮,存在于蔬菜、水果和草药中,其药理学活性已得到广泛研究,包括对各种癌细胞系的抗增殖和抗癌作用。它还具有强大的抗氧化特性和促凋亡活性,可对抗人类癌症。然而,其治疗潜力受到其在水中的低溶解度(45°C 时为 5μg/ml)和低生物利用度的限制。这项关于载有木犀草素的纳米载体的开发研究旨在克服这些限制,从而为癌症治疗开辟新的可能性。
方法:本文涵盖了几种旨在提高 LUT 溶解度和生物利用度的纳米制剂。研究了影响纳米制剂中 LUT 溶解度和生物利用度的理化特性,并更深入地研究了这些特性。此外,还研究了 LUT 的抗炎和抗氧化特性如何有助于减轻化疗的副作用。
结果:大多数纳米制剂,包括质体、脂质纳米粒、脂质体、蛋白纳米粒、聚合物胶束、纳米乳液和金属纳米粒,都显示出了提高 LUT 溶解度和生物利用度的有前途的结果。这是增强 LUT 在癌症治疗中的治疗潜力的重要一步。此外,研究发现 LUT 清除自由基的能力可以显著降低癌症治疗的副作用,进一步凸显了其改善患者预后的潜力。
结论:由于其独特的表面和物理化学特性,纳米制剂提高了 LUT 的溶解度和生物利用度。然而,需要解决纳米制剂体外和体内相关性差以及可扩展性的问题,以实现 LUT 在肿瘤学中的良好临床性能。
Curr Pharm Des. 2024
J Mater Chem B. 2023-12-6
Nanomedicine (Lond). 2017-12-4
Int J Nanomedicine. 2019-9-16
Front Pharmacol. 2025-4-22
Curr Treat Options Oncol. 2025-4
Front Pharmacol. 2025-2-12
Chem Rev. 2024-5-8
Biol Trace Elem Res. 2024-7
Pharmaceutics. 2023-5-25
Appl Biochem Biotechnol. 2023-8
Int J Nanomedicine. 2023